Drug intelligence / Profile preview

AMZ0026

Development stage: Unknown
Lead developer: Amazon Biotech
Modality: Small Molecules
Administration: Subcutaneous

Overview

AMZ0026 is a natural plant-derived pharmaceutical compound developed by Amazon Biotech as an immune modulator for the treatment of HIV/AIDS. The drug received Investigational New Drug (IND) approval from the FDA in the mid-2000s, with plans to initiate Phase I/II clinical trials to evaluate its safety and efficacy in modulating the immune systems of HIV-infected individuals. The development strategy involved seeking Fast Track designation or establishing partnerships with major pharmaceutical firms for late-stage clinical development, though no recent progress has been reported since approximately 2008.

Beyond the preview

Go deeper on AMZ0026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMZ0026.

Explore the full profile